ArticlePloS one2026
CDCA8 regulates ATP5F1A protein stability and malignant phenotypes in wilms tumor cells: Prognostic implications and mechanistic insights.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWilms tumor (WT) is a prevalent pediatric renal malignancy, yet its molecular mechanisms remain poorly defined. Identifying key prognostic genes and understanding their functional roles is critical for improving clinical management. This study aimed to identify prognostic genes in WT and to investigate whether ATP5F1A functions as a candidate downstream effector in a CDCA8-associated regulatory axis.
methodsDifferentially expressed genes (DEGs) were identified by analyzing RNA-seq datasets (GSE11151, GSE73209), comparing WT tissues with normal kidney samples. Functional enrichment was performed using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. A protein-protein interaction (PPI) network was constructed, and hub genes were identified using Cytoscape. Prognostic significance was assessed through univariate and multivariate Cox regression analyses, and a risk prediction model was developed. External expression validation of candidate hub genes was performed using GSE11024 and GSE110696. CDCA8's functional role in WT was validated by gene knockdown and overexpression experiments. Co-immunoprecipitation (Co-IP) and ubiquitination assays were conducted to explore the interaction between CDCA8 and ATP5F1A.
resultsA total of 987 DEGs were identified, with six hub genes-BUB1B, CDC45, CDCA8, KIF15, NDC80, and TOP2A-were identified. The exploratory risk score model stratified overall survival in the TARGET-WT cohort (HR = 2.973, Log-rank p = 0.000252), although time-dependent AUC values indicated modest discriminatory performance. CDCA8 was upregulated in WT tissues and associated with worse survival outcomes (HR = 2.03, p = 0.011). Functional assays suggested that CDCA8 knockdown suppressed malignant phenotypes in WiT49 cells. Mechanistically, CDCA8 knockdown reduced ATP5F1A protein levels without altering ATP5F1A mRNA expression, and this reduction was partially rescued by MG132. CDCA8 depletion was also associated with increased ATP5F1A ubiquitination, supporting a role for CDCA8 in maintaining ATP5F1A protein stability.
conclusionsThese findings suggest that CDCA8 may contribute to Wilms tumor cell phenotypes partly by maintaining ATP5F1A protein stability, providing preliminary evidence for a CDCA8-ATP5F1A regulatory axis in WT.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.